当前位置: 首页 >> 检索结果
161. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.
作者: Johannes F Fahrmann.;C Max Schmidt.;Xiangying Mao.;Ehsan Irajizad.;Maureen Loftus.;Jinming Zhang.;Nikul Patel.;Jody Vykoukal.;Jennifer B Dennison.;James P Long.;Kim-Anh Do.;Jianjun Zhang.;John A Chabot.;Michael D Kluger.;Fay Kastrinos.;Lauren Brais.;Ana Babic.;Kunal Jajoo.;Linda S Lee.;Thomas E Clancy.;Kimmie Ng.;Andrea Bullock.;Jeanine Genkinger.;Michele T Yip-Schneider.;Anirban Maitra.;Brian M Wolpin.;Samir Hanash.
来源: Gastroenterology. 2021年160卷4期1373-1383.e6页
There is substantial interest in liquid biopsy approaches for cancer early detection among subjects at risk, using multi-marker panels. CA19-9 is an established circulating biomarker for pancreatic cancer; however, its relevance for pancreatic cancer early detection or for monitoring subjects at risk has not been established.
162. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study).
作者: Nastazja Dagny Pilonis.;Marek Bugajski.;Paulina Wieszczy.;Maciej Rupinski.;Malgorzata Pisera.;Edyta Pawlak.;Jaroslaw Regula.;Michal Filip Kaminski.
来源: Gastroenterology. 2021年160卷4期1097-1105页
Primary colonoscopy and fecal immunochemical testing (FIT) are considered first-tier tests for colorectal cancer (CRC) screening. Although colonoscopy is considered the most efficacious test, FIT might achieve higher participation rates. It is uncertain what the best strategy is for offering population-wide CRC screening.
163. Initial results from a multi-center population-based cluster randomized trial of esophageal and gastric cancer screening in China.
作者: Hongmei Zeng.;Kexin Sun.;Maomao Cao.;Rongshou Zheng.;Xibin Sun.;Shuzheng Liu.;Zhiyi Zhang.;Yuqin Liu.;Guizhou Guo.;Guohui Song.;Yigong Zhu.;Xianghong Wu.;Bingbing Song.;Xianzhen Liao.;Yanfang Chen.;Mingyang Song.;Edward Giovannucci.;Guihua Zhuang.;Wenqiang Wei.;Wanqing Chen.;Jie He.
来源: BMC Gastroenterol. 2020年20卷1期398页
We initiated the first multi-center cluster randomized trial of endoscopic screening for esophageal cancer and gastric cancer in China. The objective of the study was to report the baseline screening findings in this trial.
164. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial.
作者: Kristin R Randel.;Anna L Schult.;Edoardo Botteri.;Geir Hoff.;Michael Bretthauer.;Giske Ursin.;Erik Natvig.;Paula Berstad.;Anita Jørgensen.;Per Kristian Sandvei.;Marie Ek Olsen.;Svein Oskar Frigstad.;Ole Darre-Næss.;Espen R Norvard.;Nils Bolstad.;Hartwig Kørner.;Arne Wibe.;Knut-Arne Wensaas.;Thomas de Lange.;Øyvind Holme.
来源: Gastroenterology. 2021年160卷4期1085-1096.e5页
The comparative effectiveness of sigmoidoscopy and fecal immunochemical testing (FIT) for colorectal cancer (CRC) screening is unknown.
165. The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions.
作者: M Blanca Piazuelo.;Luis E Bravo.;Robertino M Mera.;M Constanza Camargo.;Juan C Bravo.;Alberto G Delgado.;M Kay Washington.;Alicia Rosero.;Luz S Garcia.;Jose L Realpe.;Sandra P Cifuentes.;Douglas R Morgan.;Richard M Peek.;Pelayo Correa.;Keith T Wilson.
来源: Gastroenterology. 2021年160卷4期1106-1117.e3页
Helicobacter pylori eradication and endoscopic surveillance of gastric precancerous lesions are strategies to reduce gastric cancer (GC) risk. To our knowledge, this study is the longest prospective cohort of an H pylori eradication trial in a Hispanic population.
166. Colonoscopy With Polypectomy Reduces Long-Term Incidence of Colorectal Cancer in Both Men and Women: Extended Results From the Minnesota Colon Cancer Control Study.
作者: Aasma Shaukat.;Michael Shyne.;Jack S Mandel.;Dale Snover.;Timothy R Church.
来源: Gastroenterology. 2021年160卷4期1397-1399.e3页 167. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.
作者: Jieting Tang.;Yongfeng Wang.;Tao Han.;Qing Mao.;Jun Cheng.;Huiguo Ding.;Jia Shang.;Qin Zhang.;Junqi Niu.;Feng Ji.;Chengwei Chen.;Jidong Jia.;Xiangjun Jiang.;Nonghua Lv.;Yueqiu Gao.;Zhenghua Wang.;Zhong Wei.;Yingxuan Chen.;Minde Zeng.;Yimin Mao.
来源: BMC Gastroenterol. 2020年20卷1期391页
To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics.
169. A preinstalled nasopharyngeal airway in the right nasal passageway to facilitate nasogastric intubation in anesthetized and intubated patients: a prospective randomized controlled trial.
Nasogastric intubation (NGI) is usually challenging in patients under general anesthesia, with reported success rate at the first attempt to be less than 50%. The aim of this study was to investigate whether a preinstalled nasopharyngeal airway (NPA) in the right nasal passageway can facilitate NGI in anesthetized and intubated patients.
170. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.
作者: Maureen M Leonard.;Jocelyn A Silvester.;Daniel Leffler.;Alessio Fasano.;Ciarán P Kelly.;Suzanne K Lewis.;Jeffrey D Goldsmith.;Elliot Greenblatt.;William W Kwok.;William J McAuliffe.;Kevin Galinsky.;Jenifer Siegelman.;I-Ting Chow.;John A Wagner.;Anna Sapone.;Glennda Smithson.
来源: Gastroenterology. 2021年160卷3期720-733.e8页
Gluten challenge is used to diagnose celiac disease (CeD) and for clinical research. Sustained gluten exposure reliably induces histologic changes but is burdensome. We investigated the relative abilities of multiple biomarkers to assess disease activity induced by 2 gluten doses, and aimed to identify biomarkers to supplement or replace histology.
171. Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks.
作者: Klaus Gottlieb.;James Requa.;William Karnes.;Ranga Chandra Gudivada.;Jie Shen.;Efren Rael.;Vipin Arora.;Tyler Dao.;Andrew Ninh.;James McGill.
来源: Gastroenterology. 2021年160卷3期710-719.e2页
Endoscopic disease activity scoring in ulcerative colitis (UC) is useful in clinical practice but done infrequently. It is required in clinical trials, where it is expensive and slow because human central readers are needed. A machine learning algorithm automating the process could elevate clinical care and facilitate clinical research. Prior work using single-institution databases and endoscopic still images has been promising.
172. A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.
作者: Fatemeh Haidari.;Abdollah Hojhabrimanesh.;Bizhan Helli.;Seyed-Saeed Seyedian.;Kambiz Ahmadi-Angali.;Behnaz Abiri.
来源: BMC Gastroenterol. 2020年20卷1期349页
Despite promising animal data, there is no randomized controlled trial (RCT) on the effects of high protein (HP)-diet and/or β-cryptoxanthin in non-alcoholic fatty liver disease (NAFLD).
173. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
作者: Elsemieke de Vries.;Ruth Bolier.;Jorn Goet.;Albert Parés.;Jef Verbeek.;Marleen de Vree.;Joost Drenth.;Karel van Erpecum.;Karin van Nieuwkerk.;Frans van der Heide.;Nahid Mostafavi.;Jeltje Helder.;Cyriel Ponsioen.;Ronald Oude Elferink.;Henk van Buuren.;Ulrich Beuers.; .
来源: Gastroenterology. 2021年160卷3期734-743.e6页
Pruritus may seriously impair quality of life in patients with cholestatic diseases such as primary or secondary sclerosing cholangitis (PSC, SSC) and primary biliary cholangitis (PBC). Pharmacologic strategies show limited efficacy and can provoke serious side effects. We hypothesized that bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, relieves cholestasis-associated itch by alleviating hepatobiliary injury. The aim of this investigator-initiated FITCH trial (Fibrates for cholestatic ITCH) was to assess effects of bezafibrate on pruritus in patients with PSC, PBC, and SSC.
174. Underwater versus conventional endoscopic mucosal resection for small size non-pedunculated colorectal polyps: a randomized controlled trial : (UEMR vs. CEMR for small size non-pedunculated colorectal polyps).
作者: Zhixin Zhang.;Yonghong Xia.;Hongyao Cui.;Xin Yuan.;Chunnian Wang.;Jiarong Xie.;Yarong Tong.;Weihong Wang.;Lei Xu.
来源: BMC Gastroenterol. 2020年20卷1期311页
Underwater endoscopic mucosal resection (UEMR) is a recently developed technique and can be performed during water-aided or ordinary colonoscopy for the treatment of colorectal polyps. The objective of this clinical trial was to evaluate the efficacy and safety of UEMR in comparison with conventional endoscopic mucosal resection (CEMR) of small non-pedunculated colorectal polyps.
175. 99mTc-sodium phytate is a valid alternative to the gold-standard 99mTc-sulfur colloid in the measurement of gastric emptying among healthy multi-ethnic Asian population: results of a randomized cross-over trial.
作者: Norazlina Mat Nawi.;Nashrulhaq Tagiling.;Mohd Fazrin Mohd Rohani.;Wan Mohd Nazlee Wan Zainon.;Muhammad Saifuddin Zanial.;Mung Seong Wong.;Yeong Yeh Lee.
来源: BMC Gastroenterol. 2020年20卷1期293页
It is unclear if the 99mTc-sodium phytate (99mTc-SP) is as reliable as the gold-standard 99mTc-sulfur colloid (99mTc-SC) for gastric emptying scintigraphy (GES). This study is aimed to compare the emptying rates of both radiotracers in a prospective, randomized cross-over trial and to determine the normative data of a healthy multi-ethnic Asian population.
176. Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain.
作者: Ehud Rinott.;Ilan Youngster.;Anat Yaskolka Meir.;Gal Tsaban.;Hila Zelicha.;Alon Kaplan.;Dan Knights.;Kieran Tuohy.;Francesca Fava.;Matthias Uwe Scholz.;Oren Ziv.;Elad Rubin.;Amir Tirosh.;Assaf Rudich.;Matthias Blüher.;Michael Stumvoll.;Uta Ceglarek.;Karine Clement.;Omry Koren.;Dong D Wang.;Frank B Hu.;Meir J Stampfer.;Iris Shai.
来源: Gastroenterology. 2021年160卷1期158-173.e10页
We evaluated the efficacy and safety of diet-modulated autologous fecal microbiota transplantation (aFMT) for treatment of weight regain after the weight-loss phase.
177. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
作者: Katherine Li.;Colleen Marano.;Hongyan Zhang.;Feifei Yang.;William J Sandborn.;Bruce E Sands.;Brian G Feagan.;David T Rubin.;Laurent Peyrin-Biroulet.;Joshua R Friedman.;Gert De Hertogh.
来源: Gastroenterology. 2020年159卷6期2052-2064页
Ustekinumab induces and maintains histologic improvement in patients with ulcerative colitis (UC). The clinical relevance of this endpoint alone, and in combination with endoscopic improvement, is unknown.
178. Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial.
作者: Jae Ho Cho.;Cheol Min Shin.;Hyuk Yoon.;Young Soo Park.;Nayoung Kim.;Dong Ho Lee.
来源: BMC Gastroenterol. 2020年20卷1期275页
The extraesophageal manifestations of gastroesophageal reflux disease (GERD) are more difficult to manage than the typical symptoms. The efficacy of high-dose and standard-dose proton pump inhibitors against these atypical symptoms is not yet established.
179. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
作者: Stephen A Harrison.;Guy Neff.;Cynthia D Guy.;Mustafa R Bashir.;Angelo H Paredes.;Juan P Frias.;Ziad Younes.;James F Trotter.;Nadege T Gunn.;Sam E Moussa.;Anita Kohli.;Kristin Nelson.;Mildred Gottwald.;William C G Chang.;Andrew Z Yan.;Alex M DePaoli.;Lei Ling.;Hsiao D Lieu.
来源: Gastroenterology. 2021年160卷1期219-231.e1页
Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalcoholic steatohepatitis (NASH).
180. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
作者: Matthew R Henn.;Edward J O'Brien.;Liyang Diao.;Brian G Feagan.;William J Sandborn.;Curtis Huttenhower.;Jennifer R Wortman.;Barbara H McGovern.;Sherry Wang-Weigand.;David I Lichter.;Meghan Chafee.;Christopher B Ford.;Patricia Bernardo.;Peng Zhao.;Sheri Simmons.;Amelia D Tomlinson.;David N Cook.;Roger J Pomerantz.;Bharat K Misra.;John G Auninš.;Michele Trucksis.
来源: Gastroenterology. 2021年160卷1期115-127.e30页
Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon.
|